Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ENGN
ENGN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ENGN News
enGene Holdings Inc. (ENGN) Expands $125M Debt Facility, Stock Rises 14%
Jan 23 2026
seekingalpha
enGene Holdings Secures $125 Million Loan Agreement with Hercules Capital
Jan 20 2026
Businesswire
enGene Selected for FDA CDRP Program to Accelerate Drug Development
Dec 02 2025
Newsfilter
Oppenheimer Affirms Outperform Rating for enGene Holdings and Increases Price Target to $33
Nov 12 2025
Benzinga
Reasons Behind the Surge in enGene Holdings Stock Today
Nov 11 2025
TipRanks
Dow Rises Over 300 Points; Energy Vault Holdings Stock Soars
Nov 11 2025
Benzinga
EnGene Optimistic About Positive Response Rates in Bladder Cancer Study
Nov 11 2025
Benzinga
EnGene Stock Soars 53% Following Promising Bladder Cancer Gene Therapy Results
Nov 11 2025
NASDAQ.COM
Detalimogene Shows Enhanced Complete Response Rate of 62% After 6 Months
Nov 11 2025
Newsfilter
What’s Driving EnGene's Pre-market Surge?
Nov 11 2025
NASDAQ.COM
enGene Recognized as a Top Workplace by BioSpace for 2026
Nov 04 2025
Newsfilter
enGene Names Hussein Sweiti, M.D., MSc, as Chief Medical Officer
Sep 30 2025
Newsfilter
EnGene Names Hussein Sweiti as Chief Medical Officer
Sep 30 2025
NASDAQ.COM
Morgan Stanley Keeps Overweight Rating on enGene Holdings, Reduces Price Target to $18
Sep 12 2025
Benzinga
EnGene Holdings Inc. Reports Wider Q3 Loss, Falls Short of Expectations
Sep 11 2025
NASDAQ.COM
HC Wainwright & Co. Affirms Buy Rating for enGene Holdings, Keeps $25 Price Target Intact
Sep 08 2025
Benzinga
Show More News
